Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75030
UPID:
MITF_HUMAN
Alternative names:
Class E basic helix-loop-helix protein 32
Alternative UPACC:
O75030; B4DJL2; D3K197; E9PFN0; Q14841; Q9P2V0; Q9P2V1; Q9P2V2; Q9P2Y8
Background:
Microphthalmia-associated transcription factor, also known as Class E basic helix-loop-helix protein 32, plays a pivotal role in cell differentiation, proliferation, and survival. It regulates the expression of genes crucial for melanocyte development, including tyrosinase (TYR) and tyrosinase-related protein 1 (TYRP1), by binding to specific DNA sequences in their promoters.
Therapeutic significance:
Linked to diseases such as Waardenburg syndrome 2A, Tietz albinism-deafness syndrome, cutaneous malignant melanoma 8, and COMMAD syndrome, understanding the role of Microphthalmia-associated transcription factor could open doors to potential therapeutic strategies. Its involvement in pigmentary disturbances and sensorineural deafness highlights its therapeutic potential.